drug
gemcitabine
Phase 1updated 3mo agoby Continuity Biosciences LLC
Phase 1community read0 votes
🐶 often sniffed alongside
top 8- tagApproval6 co-mentions · 3 sources
- drugGEMCITABINE HYDROCHLORIDE3 co-mentions · 3 sources
- tagOncology3 co-mentions · 1 sources
- drugpaclitaxel1 co-mentions · 1 sources
- drugSOR-0071 co-mentions · 1 sources
- drugpaclitaxel albumin bound1 co-mentions · 1 sources
- drugAG [gemcitabine + nab-paclitaxel]1 co-mentions · 1 sources
- companyTianjin Medical University Cancer Institute and Hospital1 co-mentions · 1 sources
indications
indications
NSCLC
all catalysts(0)
nothing on the calendar yet
Trials studying gemcitabine
- phase2Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
- phase3A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- phase2Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
- phase3Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)
- phase3A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
- phase2GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
- phase2Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
- phase2Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)
News(6)
- Processa acquires Vidya for potential BTK inhibitor rival to Novartis’ RhapsidoProcessa Pharmaceuticals has made a push into the autoimmune space via the acquisition of Vidya Therapeutics, which delivers a potential rival to Novartis’ Rhapsido.fiercebiotech · 13d ago
- An ADC specialist sinks on safety concerns for blood cancer drugShares for ADC Therapeutics fell more than 50% after a Phase 3 trial observed a death rate that at least one analyst believes “may be difficult to accept for physicians, patients and regulators.”biopharma_dive · 2mo ago
- GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026We spoke with leading voices in GU oncology to see which presentations they are most looking forward to during the 2026 ASCO Annual Meeting.onclive · 3mo ago
- Five Under 5: Top Oncology Videos for the Week of 5/3The top 5 OncLive TV videos of the week cover insights in ovarian cancer, classical Hodgkin lymphoma, pancreatic cancer, melanoma, and myelofibrosis.onclive · 3mo ago
- Dr Pant on the Mechanism of Action of Daraxonrasib in PDACShubham Pant, MD, MBBS, explains the unique "on-state" binding mechanism of daraxonrasib.onclive · 3mo ago
- Dr Cohen on Frontline Chemotherapy Selection in Metastatic Pancreatic CancerDeirdre J. Cohen, MD, MS, discusses clinical decision-making and the comparative efficacy of FOLFIRINOX and NALIRIFOX in metastatic pancreatic cancer.onclive · 3mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that